ENT Intersect (NASDAQ:XENT – Get Note) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report released Sunday to clients and investors.
Shares of XENT opened at $27.53 on Friday. The company has a quick ratio of 1.97, a current ratio of 2.36 and a debt ratio of 6.89. The company has a 50-day simple moving average of $27.28 and a two-hundred-day simple moving average of $27.22. The stock has a market capitalization of $921.21 million, a price-earnings ratio of -10.27 and a beta of 1.51. Intersect ENT has a 52-week low of $15.92 and a 52-week high of $28.17.
Several hedge funds and other institutional investors have recently increased or reduced their stake in the company. Versor Investments LP increased its stake in shares of Intersect ENT by 40.6% in the fourth quarter. Versor Investments LP now owns 3,175,097 shares of the medical equipment supplier worth $86,712,000 after acquiring an additional 916,989 shares during the period. BlackRock Inc. increased its stake in Intersect ENT by 1.7% during the fourth quarter. BlackRock Inc. now owns 2,638,333 shares of the medical equipment supplier valued at $72,052,000 after buying an additional 44,498 shares in the last quarter. Magnetar Financial LLC purchased a new position in Intersect ENT during the third quarter worth approximately $69,571,000. Millennium Management LLC increased its stake in Intersect ENT by 1,084.1% during the third quarter. Millennium Management LLC now owns 1,575,686 shares of the medical equipment supplier valued at $42,859,000 after purchasing an additional 1,442,615 shares in the last quarter. Finally, Alpine Associates Management Inc. increased its stake in Intersect ENT by 1.6% during the fourth quarter. Alpine Associates Management Inc. now owns 1,414,600 shares of the medical equipment supplier valued at $38,635,000 after buying an additional 21,600 shares in the last quarter.
Company profile Intersect ORL (Get an assessment)
Intersect ENT, Inc. is a commercial drug delivery company, dedicated to the treatment of ear, nose and throat conditions. Its products include PROPEL and SINUVA. PROPEL is used to maintain openness and locally deliver steroids after sinus surgery. The SINUVA is used to treat adult patients who have had ethmoid sinus surgery but have recurrent sinus obstruction due to polyps.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Intersect ENT right now?
Before you consider Intersect ENT, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market ripples…and Intersect ENT was not on the list.
While Intersect ENT currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here